It was observed in T-ALL patients that the percentage of promoter methylation in the CDKN2B and CDKN2A genes ranged between 46% and 68% and between 0% and 12%, respectively, in pediatric cohorts ([52,53,54]. The gene discussed is CDKN2B; the disease is acute lymphoblastic leukemia.